Patents by Inventor Akihiko Okuyama

Akihiko Okuyama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12227517
    Abstract: A compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer having resistance to anti-PD-1 antibody/anti-PD-L1 antibody therapy is provided. The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer having resistance to anti-PD-1 antibody/anti-PD-L1 antibody therapy, and found that a pyridazinyl-thiazolecarboxamide compound has DGK ? (DGKzeta) inhibitory effect, leading to completion of the present invention. The pyridazinyl-thiazolecarboxamide compound of the present invention has DGK ? inhibitory effect, and can be used as a therapeutic agent for treatment of cancer related to activation of immune cells or cancer having resistance to anti-PD-1 antibody/anti-PD-L1 antibody therapy.
    Type: Grant
    Filed: December 24, 2020
    Date of Patent: February 18, 2025
    Assignees: Astellas Pharma Inc., KOTOBUKI PHARMACEUTICAL CO., LTD.
    Inventors: Hideyuki Watanabe, Yohei Seki, Keiichiro Okuyama, Kazuo Kurosawa, Osamu Ikeda, Hiroshi Tomiyama, Yoshinori Iwai, Akihiko Nakamura, Kozo Miyasaka
  • Patent number: 7511144
    Abstract: Reverse hydroxamic acid derivatives having specific structure represented by a general formula (Ia): (wherein A is a hydrogen atom or the like; Ar1 is an arylene or the like; Ar2 is an optionally substituted aryl, a heteroaryl or the like; R1 is a hydrogen atom, an alkyl or the like; R2a is a substituted cycloaryl, a heterocycloaryl or the like) and a general formula (I): (wherein A, Ar1, Ar2, and R1 are the same as defined above and R2 is an hydrogen atom, R2a or the like) and salts thereof, which have TNF-? converting enzyme (TACE) inhibitory activity.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: March 31, 2009
    Assignee: Kaken Pharmaceutical Co., Ltd.
    Inventors: Masanao Shimano, Noriyuki Kamei, Tomohiro Tanaka, Tatsuhiro Harada, Makoto Haino, Akihiko Okuyama, Yoshio Arakawa, Yoshiko Murakami
  • Patent number: 7335673
    Abstract: A 2,3-diphenylpropionic acid derivatives or the salts represented by general formula (1) below; and pharmaceutical compositions and cell adhesion inhibitors comprising the derivatives or the salts as the active ingredient.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: February 26, 2008
    Assignee: Kaken Pharmaceutical Co., Ltd.
    Inventors: Yoichiro Hoshina, Satoru Ikegami, Akihiko Okuyama, Tatsuhiro Harada, Atsushi Matsuo
  • Publication number: 20040242928
    Abstract: Reverse hydroxamic acid derivatives having specific structure represented by a general formula (Ia): 1
    Type: Application
    Filed: March 4, 2004
    Publication date: December 2, 2004
    Inventors: Masanao Shimano, Noriyuki Kamei, Tomohiro Tanaka, Tatsuhiro Harada, Makoto Haino, Akihiko Okuyama, Yoshio Arakawa, Yoshiko Murakami
  • Publication number: 20040072878
    Abstract: A 2,3-diphenylpropionic acid derivatives or the salts represented by general formula (1) below; and pharmaceutical compositions and cell adhesion inhibitors comprising the derivatives or the salts as the active ingredient. In the formula, A, B and C independently represents a hydrogen atom or a monovalent substituent; and X and X′ independently represents a hydrogen atom or a monovalent substituent.
    Type: Application
    Filed: August 19, 2003
    Publication date: April 15, 2004
    Inventors: Yoichiro Hoshina, Satoru Ikegami, Akihiko Okuyama, Tatsuhiro Harada, Atsushi Matsuo